Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Inclusion Criteria:

* 20\~75 years
* Histologically or cytologically confirmed solid tumors that have failed to standard therapy or for which no life prolonging treatment exists
* ECOG PS 0-2
* Life expectancy 12 weeks
* Hematopoietic: ANC ≥ 1,500/mm3, Platelet ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL, Prothrombin time, Activated partial thromboplastin time: normal range
* Hepatic: total bilirubin ≤ 1.5×ULN(except Gilbert's syndrome patients), AST, ALT ≤ 3.0×ULN(AST, ALT ≤ 5.0×ULN in case of liver metastases)
* Renal: serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min
* Signed a written informed consent

Exclusion Criteria:

* Brain or Leptomeningeal metastases
* History of Ischemic heart disease(e.g., myocardial infarction, unstable angina pectoris) or Clinically significant heart disease such as NYHA Class III and IV Congestive atrial arrhythmias, within 6 months prior to first dose of study drug
* Stable angina pectoris shown symptoms within 6 months prior to first dose of study durg, or Clinically significant abnormality on EKG or echocardiogram(e.g., LVEF \< 50% or clinically significant heart wall abnormality or heart muscle damage)
* Cerebrovascular disease such as stroke
* Grade 2 or greater motor or sensory peripheral neuropathy
* Clinically significant eye diseases(e.g., Glaucoma or Proliferative diabetic retinopathy, Atrophic macular degeneration), or other clinically significant abnormality on screening visit
* Uncontrolled hypertension(greater than 150 mmHg systolic anc 100 mmHg diastolic regardless of medication)
* acute infection or blooding tendencies that would preclude study compliance
* Serious vascular disease such as Aortic aneurysm
* Other psychiatric disorders or other conditions that would preclude study compliance
* Receiving anticoagulation with warfarin, heparin, etc.
* Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks for radiation therapy)
* Other concurrent antitumor therapy
* History of Serious hypersensitivity or allergy
* Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective contraception
* Participation in a clinical trial within 4 weeks of first dose of study drug